Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 13/20 | 0.67 |
| ▸ | PDE5A | O76074 | 1/20 | 0.52 |
| ▸ | PDE4A | P27815 | 1/20 | 0.52 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.52 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.52 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.52 |
| ▸ | AURKA | O14965 | 3/20 | 0.51 |
| ▸ | DHODH | Q02127 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL711172 | 0.87 | PRMT5 (0.60) | PRMT5PDE5APDE4APDE4BPDE4C | |
| SCHEMBL2668291 | 0.86 | PRMT5 (0.65) | PRMT5PDE5APDE4APDE4BPDE4C | |
| SCHEMBL709335 | 0.85 | PRMT5 (0.61) | PRMT5PDE5APDE4APDE4BPDE4C | |
| SCHEMBL15972282 | 0.78 | PRMT5 (1.00) | PRMT5PDE5APDE4APDE4BPDE4C | |
| SCHEMBL711302 | 0.77 | PRMT5 (0.57) | PRMT5PDE5APDE4APDE4BPDE4C | |
| SCHEMBL709311 | 0.77 | AURKA (0.54) | PRMT5AURKADHODHFAAH | |
| SCHEMBL711173 | 0.74 | AURKA (0.56) | PRMT5PDE5APDE4APDE4BPDE4C | |
| SCHEMBL711692 | 0.73 | PRMT5 (0.56) | PRMT5PDE5APDE4APDE4BPDE4C | |
| SCHEMBL711323 | 0.73 | AURKA (0.52) | PRMT5AURKADHODHFAAH | |
| SCHEMBL2668280 | 0.72 | PRMT5 (0.54) | PRMT5PDE5APDE4APDE4BPDE4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8124617-B2 | Imidazopyridine compounds | TAKEDA SAN DIEGO, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124617-B2 | Imidazopyridine compounds | TAKEDA SAN DIEGO, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-8124617-B2 | Imidazopyridine compounds | TAKEDA SAN DIEGO, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA SAN DIEGO, INC. | 2010-03-18 | — | — | US | disclosed |
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA SAN DIEGO, INC. | 2010-03-18 | — | — | US | disclosed |
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA SAN DIEGO, INC. | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | GCK, GCKR, KHK | PRMT5 2373/4885PDE5A 593/4885PDE4A 502/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.